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The era of percutaneous coronary intervention (PCI) has led
to substantial changes in the management of patients with
acute coronary syndromes and stable coronary heart disease,
with an associated range of impacts on the course and
outcomes of subsets of patients with these conditions.
Interventional cardiology has moved from percutaneous
transluminal coronary angioplasty (PTCA), with or without
administration of tissue plasminogen activator or other
thrombolytic agent, to the combined use of PTCA and
implantation of a bare-metal stent (BMS) or multiple
stents, to PTCA and implantation of 1 or more drug-
eluting stents (DES) (1–3). As first-generation DES,
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paclitaxel-eluting stents (PES) and sirolimus-eluting stents
(SES) have had extensive clinical application. The evolution
in treatment has been associated with a progressive decrease
in short-term complications, including early thrombosis,
and a decrease in short-term and long-term restenosis (2,3).
Optimal results with PTCA and stent placement requires
concomitant antithrombotic drug therapy to avoid short-
term thrombotic occlusion (4). Although the implementa-
tion of first-generation DES has resulted in a marked
decrease in the incidence of restenosis, the DES are affected
by a certain incidence of late and very late coronary
thrombosis (2–4). The first-generation DES are now being
followed by second-generation and newer DES (3).
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now numbers in the millions (2–4). Follow-up of these
patients with clinical evaluation and imaging studies has
yielded abundant data regarding clinical outcomes based on
these parameters. Clinical features and imaging results also
serve as the basis for assessment in randomized clinical
trials. Conversely, relatively few published studies have
provided information derived from direct pathological eval-
uation of stented coronary arteries, and these observations
are necessarily limited to autopsy series of a relatively limited
number of patients. The relative paucity of pathological
observations is related to a constellation of factors, including
the relatively low autopsy rates in most countries and the
technical challenges of adequately examining coronary ar-
teries with implanted stents. Nevertheless, direct patholog-
ical examination has an important role in providing obser-
vations and insights not available by any other approach.
Insights from pathology studies have served as a basis for
evolution in approaches to PCI. Pathology studies showed
that PTCA results in arterial injury of variable degree,
including endothelial damage, plaque fractures, variable
damage and dissection of the media, and mural platelet and
fibrin thrombus deposition (5–7). The vascular responses to
PTCA were identified as: 1) recoil and negative remodeling
or contraction of the coronary artery segment after dilation;
2) endothelial damage, often with associated thrombosis;
and 3) concomitant progressive fibrocellular intimal thick-
ening involving perturbation of vascular smooth muscle cells
leading to deposition of extracellular matrix and variable
proliferation (8,9).
These vascular responses to PTCA, characterized by
remodeling and neointimal proliferation, were found to be
responsible for the rapidly progressive and frequent reste-
nosis within several months after PTCA. With the modi-
fication of PCI to include BMS placement, the develop-
ment of restenosis was reduced in frequency and average
time of onset, largely due to elimination of the elastic recoil
and negative remodeling (9). However, in coronary artery
segments with BMS and restenosis, pathology studies dem-
onstrated the same neointimal proliferation as the culprit
process (10,11). Proliferation of smooth muscle cells and
extracellular matrix synthesis were identified as key compo-
nents of the process (9–11). Recent studies have demon-
strated colonization of the neointima by extravascular cells,
including endothelial progenitor, dendritic, and neural
crest-derived cells as well as inflammatory cells, and have
identified a counterbalancing role for apoptosis, adding
further complexity to the process (12,13). Predisposing
factors for in-stent restenosis were identified as stenting that
is accompanied by medial damage or penetration of the
stent struts into the lipid core of plaques. Both of these
factors were implicated in inducing increased arterial in-
flammation, which in turn can drive increased intimal
proliferation (10).
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coating the stents with a drug with antiproliferative prop-
erties will significantly reduce post-PTCA intimal prolifer-
ation and subsequent restenosis (2). First-generation DES,
including PES and SES, have markedly decreased the
occurrence of post-PTCA restenosis. However, DES have
been found to have the complication of late thrombosis and
very late thrombosis (4). Virmani et al. (10,11,14,15) have
contributed significantly to the investigation of the patho-
logical correlates of BMS and DES implantation, including
comparative findings in DES and BMS. In a previous study,
multiple features of coronary segments with DES were
characterized from a registry of 81 autopsied patients with
DES (14). The basic feature of neointimal thickening was
again identified. However, multiple logistic modeling with
generalized estimation equations demonstrated that im-
paired endothelialization was the best predictor of throm-
bosis. The measured parameter that best correlated with
endothelialization was the ratio of uncovered to total stent
struts per histological section. Nevertheless, multiple factors
contributing to delayed re-endothelialization with DES
have been identified, including an inflammatory response to
the PTCA and stent placement as well as hypersensitivity
reactions to the polymers employed in the DES, before the
recent advent of polymer-free DES (16). The findings,
taken together, have pointed to the importance of hetero-
geneity of healing and incomplete healing of the stented
segment in the pathophysiology of late stent thrombosis.
In this issue of the Journal, Nakazawa et al. (15) report on
another pathological change, namely, atherosclerosis in the
neointima, or neoatherosclerosis, in a registry series of 299
autopsies with 406 coronary stented segments (lesions),
including 197 BMS and 209 DES (103 SES and 106 PES)
with implant duration 30 days. Neoatherosclerosis was
identified as clusters of peristrut lipid-laden foamy macro-
phages within the neointima with or without necrotic core
formation. Approximately one-third of the neoatheroscle-
rotic lesions lacked advanced features and appeared to be
equivalent to fatty streaks in native arteries. The other
two-thirds of the lesions had features of advanced lesions,
including fibroatheromas, thin-cap fibroatheromas, and
ruptures with thrombosis. Several of these lesions had
features equivalent to vulnerable or unstable plaques of
native coronary arteries (17). In all cases, however, there was
no communication between the lesion within the stent and
the underlying native atherosclerotic plaque.
In this registry series, the overall incidence of neoathero-
sclerosis was significantly greater in DES (31%) than in
BMS (16%) lesions (p  0.001). The median duration of
tent implantation showing neoatherosclerosis was shorter
n DES than in BMS: 420 days for DES and 2,160 days for
MS (p  0.001). Complicated lesions characterized as
hin-cap fibroatheromas or plaque rupture were more fre-
uent but not significantly different in BMS (n  7, 4%)
ompared with DES (n  3, 1%; p  0.17), but with
elatively shorter implant times for DES (1.5  0.4 years)ompared with BMS (6.1  1.5 years). By multiple logistic
egression analysis, independent determinants of neoathero-
clerosis were younger age (p  0.001), longer implant
durations (p  0.001), SES usage (p  0.001), PES usage
(p  0.001), and underlying unstable plaques (p  0.004).
Thus, based on data from this autopsy registry series,
neoatherosclerosis was found to be a more frequent patho-
logical change in DES than in BMS and to occur earlier in
DES than in BMS. Although unstable features of neoath-
erosclerosis occurred with BMS and DES, unstable neoath-
erosclerosis occurred with shorter implant duration with
DES than BMS. These findings suggested a higher rate and
more rapid onset of significant complications with first-
generation DES than BMS. However, the incidence of thin-
cap fibroatheromas and ruptured plaques with thrombosis
were low for both groups, namely, BMS (n  7, 4%) and
DES (n  3, 1%). The authors reached the general
conclusion that the frequency of the development of neo-
atherosclerosis is such that the phenomenon likely repre-
sents an additional factor contributing to late thrombotic
events in some patients and after shorter duration of
implantation with DES than BMS implantation. However,
the findings and conclusions regarding neoatherosclerosis
need to be put into the context of other characteristics of the
case series. The incidence of causes of death from stent-
related thrombosis, restenosis without diffuse coronary ar-
tery disease, and diffuse coronary artery disease with reste-
nosis were different in the 2 groups, with stent-related
thrombosis higher in the DES group (20% vs. 4%) and the
other 2 causes higher in the BMS group (13% vs. 3% and
14% vs. 3%). The DES group also had significantly more
native unstable plaques and significantly longer stents im-
planted.
Clinical trials present a different perspective on the
incidence of various complications of coronary stenting. A
large meta-analysis including 18,023 patients in 38 random-
ized controlled trials with follow-up of up to 4 years and
additional data on clinical outcomes for 29 other trials
focused on risks of death, myocardial infarction, and stent
thrombosis comparing BMS, SES, and PES (18). Mortality
was similar in the 3 groups. The SES were associated with
the lowest risk of myocardial infarction. There were no
significant differences in the risk of definite stent thrombo-
sis, confirmed by angiography or autopsy, during the inter-
val of 0 days to 4 years. However, the risk of late definite
stent thrombosis (30 days) was increased with PES. Both
SES and PES reduced the target lesion revascularization
rate compared with BMS, but the effect was more pro-
nounced with SES than with PES. In another meta-analysis
of 35 trials involving 3,852 subjects with diabetes mellitus
and 10,947 without diabetes, hazard ratios were near 1 for
all comparisons in subjects with diabetes (19). Both types of
DES were associated with a decrease in revascularization
rates compared with BMS in subjects with and without
diabetes. These meta-analyses support the overall safety and
effectiveness of DES in patients with and without diabetes,
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are also supported by data from the largest registry (Swedish
Coronary Angiography and Angioplasty Registry) reported
by Langerqvist et al. (20). Similar results have been obtained
with next-generation DES (21). Clinical studies also have
provided direction for selection of patients for either BMS
or DES according to criteria aimed at obtaining good
outcomes with either BMS or DES (22–24).
The apparent discrepancies between the pathological and
clinical studies need to be reconciled. A recommended
approach is to focus on the strengths and limitations of the
2 types of studies. Randomized, controlled clinical trials,
appropriately powered with large numbers of patients,
clearly represent the strongest and statistically validated
approach to determining clinical outcomes of a drug or
intervention as well as comparative outcomes of different
therapeutic approaches. A caveat, however, is that clinical
trials necessarily provide a detailed analysis of a subset of an
entire treated population in which trends may occur and not
be captured in the clinical trial.
Conversely, whereas pathological studies, particularly au-
topsy series, are typically subject to selection bias regarding
population outcomes, the pathological studies are uniquely
capable of providing information regarding pathobiological
phenomena that predispose to both good and adverse
clinical outcomes. In other words, the strength and impor-
tance of the pathological studies is on identifying underlying
mechanistic factors rather than on incidence of clinical
outcomes, which is one of the strengths of the clinical trials.
These considerations certainly pertain to the discussion
regarding the coronary vascular responses to BMS and
DES, including PES and SES. A related consideration is
that advanced imaging techniques increasingly are being
used to investigate vascular responses to interventions in
living patients. This includes intravascular ultrasound cou-
pled with what is called virtual histology as well as other
approaches (25,26). Although virtual histology is an appeal-
ing concept, there remains a need for direct pathological
confirmation of such imaging studies (17).
The pathological findings regarding vascular responses to
BMS and DES clearly point to the importance of complete
and effective covering of the stented neointima by endothe-
lium, namely, endothelialization, or the lack thereof, in
leading to good or adverse outcomes, including late throm-
bosis. However, the approach of evaluating endothelializa-
tion by determining numbers and percent of covered and
uncovered struts is not a definitive approach to evaluating
the extent and quality of endothelial covering of stented
segments. Additional approaches are warranted, including
en face scanning electron microcopy and immunocytochem-
istry in pathological studies as well as functional assessments
(27–30). There also is an important place for experimental
studies to evaluate pathophysiological phenomena, includ-
ing extent of endothelial formation and maturation and
control of fibrocellular intimal thickening, as new ap-
proaches to DES are being developed (31–33). Adversereactions to stents involve multiple interrelated mechanisms
including stent characteristics, procedural factors, individual
susceptibility influenced by genetic predisposition and clin-
ical factors, and the inflammatory response (9,16). Delayed
or impaired re-endothelialization needs to be considered in
the context of this complex milieu. Continued attention to
the basic pathobiology of vascular responses to injury and
interventions is of paramount importance in developing
improved therapeutic interventions and optimal clinical
outcomes.
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